Skip to main
VERV
VERV logo

Verve Therapeutics (VERV) Stock Forecast & Price Target

Verve Therapeutics (VERV) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 8%

Bulls say

Verve Therapeutics is viewed positively due to its innovative approach to transforming the treatment of cardiovascular disease through single-course gene editing medicines, addressing critical weaknesses in the current chronic care model. The company has a solid financial position, boasting $540 million in cash, providing a runway through mid-2027 which supports its ongoing research and development efforts. Additionally, the recent licensing agreement with BEAM for base editing technology, coupled with an industry-high $300 million upfront payment and potential $1.05 billion in milestones, demonstrates significant pharmaceutical interest and validates Verve's strategic direction in the gene-editing market.

Bears say

Verve Therapeutics Inc. reported a significant net loss of $50 million for 4Q24, translating to a loss of $0.58 per share, with projections indicating a full-year 2025 net loss of $2.38 per share, underscoring the company's non-revenue generating status. The company's pipeline remains in early stages without near-term catalysts, heightening concerns about the unpredictability of future revenues and expenses amidst high regulatory hurdles and market risks. Additionally, potential delays in clinical assessments and unfavorable data from ongoing programs, combined with the possibility of long-term dilution risks, further exacerbate the negative outlook for the company's stock.

Verve Therapeutics (VERV) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verve Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verve Therapeutics (VERV) Forecast

Analysts have given Verve Therapeutics (VERV) a Hold based on their latest research and market trends.

According to 13 analysts, Verve Therapeutics (VERV) has a Hold consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verve Therapeutics (VERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.